Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline - Wikidata - wikimedia - TriplyDB

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline

http://www.wikidata.org/entity/Q34277844

about

Pegvisomant in acromegaly: an update.Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study.Current and future medical treatments for patients with acromegaly.Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.How to improve effectiveness of pegvisomant treatment in acromegalic patients.Daily life reflections of acromegaly guidelines.Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease.

P2860

Q33725999-692BFD20-6781-4E95-9438-30CC1830C7F9 Q36119677-BD6B6679-42FE-4AB4-B150-2F901D0A3DB8 Q38847622-A2FBA9CA-A871-4E6A-96D4-47840887BEF0 Q39146196-E555F350-B5CE-4D06-91CE-D42561E98013 Q41009206-558D8D30-CEFF-48DB-90B5-88341B2BDB1B Q53720920-0EE9FD25-E578-490D-A3EA-6F347B597293 Q53765411-01C49E73-E8D0-41D5-B5CC-A922428AF26A Q55146337-1B12E99F-FF04-4D41-A3A4-ACF387E64F92

P2860

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline

http://www.wikidata.org/entity/Q34277844

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline

@ast

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline

@en

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline

@nl

type

label

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline

@ast

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline

@en

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline

@nl

prefLabel

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline

@ast

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline

@en

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline

@nl

P1433

Q34277844-362CE0E4-0161-4522-86CB-9FB78282B8D3

P1476

Q34277844-30A5751A-26F0-4DA3-863D-F6E103C09F78

P2093

Q34277844-03355254-6337-4FDE-B6B8-3E8D4F29134C

Q34277844-2429B7AA-1054-4962-B209-14D4C08AB97D

Q34277844-384F24BB-4630-4955-8AE8-EFAED394AAB7

Q34277844-4E9957FF-DD4F-4290-A34C-6824F9AC486D

Q34277844-6C5A5F57-BA63-4032-AD65-4AE2C564637F

Q34277844-7606CB77-6715-4574-A119-DC51BCA022DB

P2860

Q34277844-0099A0C5-EDBE-43DE-AB64-7D7A3C6EF2E1

Q34277844-0786CBE1-5184-416C-B7FB-3CB38C79CA28

Q34277844-07A2D1F0-D6CC-49FF-9482-440ECAA6FC3C

Q34277844-094E3E46-DC22-4078-AB13-352EA7604FA9

Q34277844-0F4EC1D8-A265-4C49-AB1B-2CC3FE5A088D

Q34277844-10030DBB-01E7-42E2-8536-83EEF4CBCEF6

Q34277844-110B37DC-604E-4122-9E5E-90086621CF44

Q34277844-143C9BC8-CD2E-442F-A3F3-DCEE34A9E467

Q34277844-1610CF14-5F9E-4C2C-9C39-934CAAB5BF01

Q34277844-161467C1-4471-4340-BB7B-A066449796FC

P2888

Q34277844-91E89F2B-151D-4ACE-83E5-14FDCF35FC0C

P304

Q34277844-A983202E-4192-4A35-83D0-260BCB8C6BF4

P31

Q34277844-C8FE60B7-3D29-47B6-A269-72FE8A27F301

P356

Q34277844-8486C2C0-B911-43F4-AD75-37BC9B179C68

P433

Q34277844-49545944-B60C-4CF1-B2BF-C2F07C5D054D

P478

Q34277844-AF3BD575-B3EA-46CA-94A1-77CDE68E93B6

P50

Q34277844-2F734E39-9D16-4CE1-8684-2778DDA35B22

Q34277844-655A1D95-08B0-4724-BCD0-39C1AB555E68

Q34277844-6DCBCBC8-FEA8-4C5D-9790-8C1A0D1FF691

P577

Q34277844-7F41AD7E-0416-4167-A65C-3B52758E381B

P5875

Q34277844-526CB6D2-230F-479A-85A0-E2E49442D149

P6179

Q34277844-726A19FB-BD53-4DA2-888E-50D3FEAF25A7

P698

Q34277844-1599453F-575E-49D5-A62A-EFBA884D7312

P921

Q34277844-55766974-F996-4238-88CD-9D67589CB54E

P932

Q34277844-10FFECD9-A054-4285-BC57-8EE419ACEDAD

P356

S40618-014-0146-X

P1433

Journal of Endocrinological Investigation

P1476

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline

@en

P2093

A Giustina

http://www.w3.org/2001/XMLSchema#string

E De Menis

http://www.w3.org/2001/XMLSchema#string

L De Marinis

http://www.w3.org/2001/XMLSchema#string

P Beck Peccoz

http://www.w3.org/2001/XMLSchema#string

R Pivonello

http://www.w3.org/2001/XMLSchema#string

S Grottoli

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation

Human growth hormone and extracellular domain of its receptor: crystal structure of the complex

Acromegaly pathogenesis and treatment

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study

Meta-analysis on the effects of octreotide on tumor mass in acromegaly

Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH.

Acromegaly and McCune-Albright syndrome.

Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone.

Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.

P2888

s40618-014-0146-x

P304

1017-1030

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40618-014-0146-X

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

Maria Rosaria Ambrosio

Salvatore Cannavo

P577

2014-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266029517

http://www.w3.org/2001/XMLSchema#string

P6179

1028218281

http://www.w3.org/2001/XMLSchema#string

P698

25245336

http://www.w3.org/2001/XMLSchema#string

P921

P932

4182612

http://www.w3.org/2001/XMLSchema#string